Abstracts Archive - Page 107 of 2607 - ACR Meeting Abstracts

Abstract Number: 1174 • ACR Convergence 2025
High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study
Mitali Sen¹, Gordon Ruan², Samuel Reynolds³, Haadi Ali³, Xi Yang³, Diana Morlote¹, Aishwarya Ravindran¹, Lauren Shea¹, Matthew Koster⁴, Jithma Abeykoon², Hind Salama⁵, Xin-Xin Cao⁶, Asra Ahmed³, Ronald Go² and Gaurav Goyal¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Mayo Clinic, Rochester, ³University of Michigan, Michigan, ⁴Mayo Clinic, Rochester, MN, ⁵National Guard Health Affairs, Riyadh, Saudi Arabia, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Rosai-Dorfman Disease (RDD), formerly known as sinus histiocytosis with massive lymphadenopathy, was initially thought to be inflammatory or autoimmune in nature. The discovery of…
Abstract Number: 1219 • ACR Convergence 2025
Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Vasiliki Syrmou¹, Ioannis Alexiou², Christos Liaskos³, Eleni Patrikiou³, THEODORA SIMOPOULOU⁴, Christina Katsiari⁵ and Dimitrios Bogdanos⁶, ¹University General Hospital of Larisa, University of Thessaly, Faculty of Medicine, Larisa, Greece, ²University General Hospital of Larisa, Larissa, Greece, ³University of Thessaly, Faculty of Medicine, Larisa, Greece, ⁴University Hospital of Larissa, Greece, Larissa, Greece, ⁵University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁶Professor, Larissa, Greece
Background/Purpose: Anti-Ro52 antibodies are commonly detected in idiopathic inflammatory myopathies (IIMs), yet their clinical significance remains incompletely defined. There is evidence that it coexists with…
Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Blake Baay¹, Lorien Nassi² and Zachary Most³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
Abstract Number: 1057 • ACR Convergence 2025
Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
Rebecca Summit¹, Dylan Tierney², Taussia Boadi², Tyler Green², Karli Retzel², Virginia Bills², Nancy Shadick², Leah Santacroce³, Sara Schoenfeld⁴ and Candace Feldman⁵, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham & Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA, ⁴Mass General Hospital, Boston, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston
Background/Purpose: Social risk factors, such as housing instability, influence care access and outcomes in people with rheumatic conditions. In June 2022, 9 rheumatology clinics in…
Abstract Number: 1077 • ACR Convergence 2025
Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
Mrinalini Dey¹, Sam Norton², Andrew Cope², MAYA BUCH³, Richard Osborne⁴, James Galloway² and Elena Nikiphorou², ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²King's College London, London, United Kingdom, ³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ⁴La Trobe University, Melbourne, Victoria, Australia
Background/Purpose: Work status and employment can be impacted in people with inflammatory arthritis (IA). We aimed to assess the association between health literacy and work…
Abstract Number: 1001 • ACR Convergence 2025
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Hongyan Shang¹, Xiao Huang², Duqing Jiang¹, Jianming Sun², Yurong Qin², Guojin Wu², Chengze Ni¹, Jing Guan², Jordan Zhu³, Xiaoqiang Kang² and Hong Ling², ¹Nanjing Leads Biolabs Co., Ltd., nanjing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ³Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Programmed cell death protein 1 (PD-1) is expressed on activated T cells and serves as a key co-inhibitory checkpoint molecule in immune regulation. Aberrant…
Abstract Number: 1183 • ACR Convergence 2025
Risk of Inflammatory Bowel Disease in Psoriatic Arthritis Patients Treated with IL-17 Inhibitors
Rusudan Tskitishvili¹, Abdallah Hussein², Irakli Tskhakaia³, Nanuka Tsibadze³, Eric Osgood² and Humaira Khan⁴, ¹Virtua Health, Camden, NJ, ²Virtua Health, Camden, ³Jefferson Health - Einstein, Philadelphia, PA, ⁴Virtua Health, Voorhees
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive inflammatory arthritis that significantly impairs quality of life and contributes to substantial morbidity. Interleukin-17 (IL-17) plays a…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
Abstract Number: 1173 • ACR Convergence 2025
Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging
Matthew Charles Baker¹, Lauren Taylor², Haziq Siddiqi², Jison Hong² and Brian Pogatchnik², ¹Stanford University, Menlo Park, CA, ²Stanford University, Stanford, CA
Background/Purpose: IgG4-related disease (IgG4-RD) classically presents with a mass or diffusely enlarged organ, but it also affects blood vessels of all sizes. Coronary artery involvement…
Abstract Number: 1011 • ACR Convergence 2025
Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Ethan Eickmann¹, Daniel Betensky¹, Karen Smith¹, Candace Feldman¹, Jason Kim², Ankur Pandya³, Jeffrey Katz⁴ and Elena Losina⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Arthritis Foundation, Atlanta, GA, ³Harvard School of Public Health, Boston, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵BWH, Boston, MA
Background/Purpose: US federal law currently does not allow Medicare Part D coverage for weight loss medications without additional indications, such as diabetes. Several glucagon-like peptide-1…
Abstract Number: 1192 • ACR Convergence 2025
Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Sandra G Pasoto¹, Thais B Gorayeb², Ana Paula Luppino-Assad³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro¹, Leonard V Kupa⁵, Bruno S Borges⁶, Samuel K Shinjo⁷, Fernando H De Souza², Renata Miossi², Eloisa Bonfa⁸ and Clovis Artur Silva⁹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SÃO PAULO, Brazil, ⁸Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁹University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Although herpes zoster vaccination has been evaluated in immunocompromised populations, studies assessing vaccine immunogenicity and safety in idiopathic inflammatory myopathies (IIM) are restricted to…
Abstract Number: 1212 • ACR Convergence 2025
Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Maria Rosa Pellico¹, Cristina Bochicchio², Claudia Iannone³, Lekshmi Minikumari Rahulan⁴, Marco Fornaro⁵, Ilaria Cavazzana⁶, Edoardo Conticini⁷, Masataka Kuwana⁸, Akira Yoshida⁹, Silvia Cavalli², Silvia Grazzini⁷, Alessia Gatti¹⁰, Giulio Lopinto¹¹, Paolo Semeraro¹², Thomas Patrick Sheeran¹³, Florenzo Iannone¹⁴, Vikas Agarwal¹⁵, Roberto Caporali¹⁶, Nicoletta Del pAPA¹ and Latika Gupta¹⁷, ¹ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ²ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ³University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ⁵Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ⁶Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁰Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ¹¹Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, ¹²Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Italy, ¹³Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; Rheumatology Department, Walsall Manor Hospital, Walsall, UK, Wolverhampton, United Kingdom, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare and heterogeneous diseases. One of the greatest challenges in IIM management is defining and predicting…
Abstract Number: 1169 • ACR Convergence 2025
Periodontitis in neutropenic DADA2 patients
Lorena Wilson¹, Amanda Ombrello², Patrycja Hoffmann³, Cornelia Cudrici³, Tina Romeo⁴ and Daniel L. Kastner⁵, ¹National Institutes of Health, Silver Spring, ²National Institutes of Health, Rockville, MD, ³National Insitutes of Health, Bethesda, ⁴NIH, Bethesda, MD, ⁵National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by pathogenic mutations in ADA2. Severe and refractory neutropenia is a hematologic…
Abstract Number: 1206 • ACR Convergence 2025
Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Juliane Bremer¹, Judith Nagel², Jana Zschüntzsch³, Kamil K Zajt¹, Tayfun Palaz¹, Thomas Blank⁴, Aylin Ikis¹, Laura A Fischer³, Anna SM Sensmeyer³, Lara Wiechers³, Josef J Reichelt³, Kai P Hofmann⁵, Monika J Wolf⁶, Corinna Leuchtenberger⁷, Priyanka Tripathi¹, Claudia Einer⁸, Hans Zischka², Ulrike Rothermel⁷, Anna L Eck⁷, Regina Reimann⁹, Veronika Kana⁶, Elisabeth Rushing⁶, Adriano Aguzzi⁶, Marco Prinz⁴, David Liebetanz³, Francesca Odoardi³, Chao-Chung Kuo¹, Joachim Weis¹, Florian Kraft¹, Jens Schmidt¹⁰ and Mathias Heikenwälder⁷, ¹University Hospital RWTH Aachen, Aachen, Germany, ²Technical University of Munich, München, Germany, ³University Medical Center Göttingen, Göttingen, Germany, ⁴University of Freiburg, Freiburg, Germany, ⁵DKFZ Heidelberg, Göttingen, Germany, ⁶University Hospital Zürich, Zürich, Switzerland, ⁷DKFZ Heidelberg, Heidelberg, Germany, ⁸Helmholtz Munich, München, Germany, ⁹University Hospital Zürich, Zürich, Germany, ¹⁰Immanuel University Hospital Rüdersdorf, Brandenburg Medical School, Rüdersdorf bei Berlin, Germany
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disorder characterized by inflammation and degeneration with altered proteostasis. To better understand the interrelationship between these…
Abstract Number: 1182 • ACR Convergence 2025
Cardiac Sarcoidosis in Black Patients: A Biopsy-Confirmed Cohort Study
Roshan Subedi¹, Haya Haddad², Rachel Barish¹, Tania Vora¹, Nana Afari-Armah³, Ajay Kadakkal¹, Farooq Sheikh¹ and Florina Constantinescu¹, ¹Medstar Washington Hospital Center, Washington, DC, ²Medstar Washington Hospital Center, Silver Spring, MD, ³Medstar Washington Hospital Center, Washington
Background/Purpose: Sarcoidosis is an inflammatory disease characterized by non-necrotizing granulomatous inflammation that can affect any organ. Approximately 5% of patients with sarcoidosis develop clinically significant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].